Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: What is the evidence?

Expert Review of Neurotherapeutics

Volumn 9, Issue 1, 2009, Pages 55-71

  Citrome, Leslie ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsant; Antipsychotic; Carbamazepine; Clinical trial; Lamotrigine; Lithium; Schizophrenia; Topiramate; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; ETIRACETAM; FLUPHENAZINE DECANOATE; FUROSEMIDE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PERAZINE; PIMOZIDE; PREGABALIN; QUETIAPINE; RISPERIDONE; THIAZIDE DIURETIC AGENT; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ACUTE KIDNEY FAILURE; AGGRESSION; AGRANULOCYTOSIS; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; APLASTIC ANEMIA; ATAXIA; BIPOLAR DISORDER; BLURRED VISION; COGNITIVE DEFECT; COMA; CONFUSION; CONSCIOUSNESS; CONSTIPATION; COORDINATION DISORDER; DELIRIUM; DIARRHEA; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMORRHAGIC PANCREATITIS; HUMAN; HYPERAMMONEMIA; HYPONATREMIA; INCONTINENCE; KIDNEY INJURY; LEUKOPENIA; LIVER TOXICITY; MACULOPAPULAR RASH; MENSTRUATION DISORDER; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NYSTAGMUS; PARESTHESIA; POLYURIA; RASH; REVIEW; RHINITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; LITHIUM COMPOUNDS; SCHIZOPHRENIA;

EID: 58149230875     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.1.55     Document Type: Review

References (127)

1. Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv. Rev. Psychiatry 13(1), 28-42 (2005).
2. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1), 27-47 (2008).
3. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J. Pharm. Technol. 11(2), 55-59 (1995).
4. Citrome L, Volavka J. Clinical management of persistent aggressive behavior in schizophrenia. Part II: long-term pharmacotherapeutic strategies. Essent. Psychopharmacol. 5(1), 17-30 (2002).
5. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr. Q 69(4), 283-300 (1998).
6. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 51(5), 634-638 (2000). • One of the first reports describing the relatively high utilization rates for adjunctive mood stabilizers in the treatment of schizophrenia.
7. Citrome L, Jaffe A, Levine J. Datapoints - mood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994-2001. Psychiatr. Serv. 53(10), 1212 (2002).
8. Citrome L. Antipsychotic polypharmacy versus augmentation with anticonvulsants: the US perspective. Int. J. Neuropsychopharmacol. 7(Suppl. 1), S69 (2004).
9. Wessels T, Grunler D, Bunk C et al. Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004. Psychiatr. Q 78(2), 91-99 (2007).
10. Davids E, Bunk C, Specka M, Gastpar M. Psychotropic drug prescription in a psychiatric university hospital in Germany. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(6), 1109-1116 (2006).
11. Grohmann R, Engel RR, Geissler KH, Rüther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37(Suppl. 1), S27-S38 (2004).
12. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr. Scand. 117(6), 412-419 (2008). • Introductory primer on number needed to treat.
13. Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int. J. Clin. Pract. 60(8), 933-940 (2006).
14. Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int. J. Clin. Pract. 62(5), 837-840 (2008).
15. Hakola HP, Laulumaa VA. Carbamazepine in treatment of violent schizophrenics. Lancet 1(8285), 1358 (1982).
16. Luchins DL. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol. Bull. 20(3), 569-571 (1984).
17. Okuma T, Yamashita I, Takahashi R et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr. Scand. 80(3), 250-259 (1989). •• Largest published study regarding the adjunctive use of carbamazepine for the treatment of schizophrenia.
18. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J. Clin. Psychiatry 44(9), 326-331 (1983).
19. Ohlmeier MD, Jahn K, Wilhelm-Gossling C et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology 55(2), 81-88 (2007).
20. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res. 22(4), 303-310 (1987).
21. Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol. Psychiatry 35(1), 22-26 (1994).
22. Simhandl C, Meszaros K, Denk E, Thau K, Topitz A. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia. Can. J. Psychiatry 41(5), 317 (1996).
23. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J. Clin. Psychopharmacol. 19(4), 310-315 (1999).
24. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst. Rev. 3, CD001258 (2007). •• Comprehensive meta-analysis with many pertinent references.
25. Fenn HH, Robinson D, Luby V et al. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am. J. Psychiatry 153(5), 711-713 (1996).
26. Weisler RH, Hirschfeld R, Cutler AJ et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 20(3), 219-231 (2006).
27. Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J. Clin. Psychopharmacol. 27(3), 279-283 (2007).
28. Bowden CL, Karren NU. Anticonvulsants in bipolar disorder. Aust. NZ J. Psychiatry 40(5), 386-393 (2006).
29. Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br. J. Psychiatry 129, 114-119 (1976).
30. Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol. Psychiatry 14(3), 509-523 (1979).
31. Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J. Clin. Psychopharmacol. 21(1), 21-26 (2001).
32. Chong SA, Tan CH, Lee EL, Liow PH. Augmentation of risperidone with valproic acid. J. Clin. Psychiatry 59(8), 430 (1998).
33. Ko GN, Korpi ER, Freed WJ, Zalcman SJ, Bigelow LB. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenia patients. Biol. Psychiatry 20(2), 209-215 (1985).
34. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia revisited. Br. J. Psychiatry 150, 542-546 (1987).
35. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 31(4), 122-125 (1998).
36. Wassef AA, Dott SG, Harris A et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J. Clin. Psychopharmacol. 20(3), 357-361 (2000).
37. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28(1), 182-192 (2003). •• Largest published study regarding the adjunctive use of valproate for the treatment of schizophrenia.
38. Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int. Clin. Psychopharmacol. 22(6), 356-362 (2007).
39. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Effects of adjunctive valproate on hostility in patients with schizophrenia receiving olanzapine or risperidone: a double-blind multi-center study. Psychiatr. Serv. 55(3), 290-294 (2004).
40. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr. Q 77(1), 81-95 (2006).
41. Wassef AA, Winkler DE, Roache AL et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions. Am. J. Psychiatry 162(2), 330-339 (2005).
42. Abbott Laboratories. Depakote ER. Divalproex sodium extended-release tablets, formulary information. Abbott Park, Ill, Abbott Laboratories (2000).
43. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 49(1), 1-10 (2002).
44. Citrome L, Tremeau F, Wynn PS, Roy B, Dinakar H. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. J. Clin. Psychopharmacol. 24(3), 255-259 (2004).
45. Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst. Rev. 3, CD004028 (2008). •• Comprehensive meta-analysis with many pertinent references.
46. Kanner AM, Balabanov A. Valproate: a practical review of its uses in neurological and psychiatric disorders. Expert Rev. Neurother. 2(2), 151-165 (2002).
47. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 22(4), 325-334 (2008).
48. Cohen LS. Treatment of bipolar disorder during pregnancy. J. Clin. Psychiatry 68(Suppl. 9), 4-9 (2007).
49. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can. J. Psychiatry 39(4), 236-238 (1994).
50. Dursun SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch. Gen. Psychiatry 56(10), 950 (1999).
51. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J. Psychopharmacol. 15(4), 297-301 (2001).
52. Kalyoncu A, Mirsal H, Pektas O, Unsalan N, Tan D, Beyazyürek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J. Psychopharmacol. 19(3), 301-305 (2005).
53. Thomas R, Howe V, Foister K, Keks N. Adjunctive lamotrigine in treatmentresistant schizophrenia. Int. J. Neuropsychopharmacol. 9(1), 125-127 (2006).
54. Heck AH, de Groot IW, van Harten PN. Addition of lamotrigine to clozapine in inpatients with chronic psychosis. J. Clin. Psychiatry 66(10), 1333 (2005).
55. Chan YC, Miller KM, Shaheen N, Votolato NA, Hankins MB. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report. Schizophr. Res. 78(2-3), 343-345 (2005).
56. Stuve W, Wessels A, Timmerman L. Remission of positive symptomatology of a schizophrenic psychosis after withdrawing lamotrigine: a case report. Eur. Psychiatry 19(1), 59-61 (2004).
57. Tiihonen J, Hallikainen T, Ryynanen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry 54(11), 1241-1248 (2003). • First published controlled study of adjunctive lamotrigine for the treatment of schizophrenia.
58. Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry 56(6), 441-446 (2004).
59. Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, Alem ZM. Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? Therapy 2(3), 399-406 (2005).
60. Zoccali R, Muscatello MR, Bruno A et al. The effect of lamotrigine augmentation of clozapine in a sample of treatmentresistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr. Res. 93(1-3), 109-116 (2007).
61. Goff DC, Keefe R, Citrome L et al. Lamotrigine as add-on therapy in schizophrenia: results of two placebo-controlled trials. J. Clin. Psychopharmacol. 27(6), 582-589 (2007). •• Largest published study regarding the adjunctive use of lamotrigine for the treatment of schizophrenia.
62. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst. Rev. 4, CD005962 (2006).
63. Malik S, Arif H, Hirsch LJ. Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Expert Rev. Neurother. 6(11), 1609-1627 (2006).
64. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can. J. Psychiatry 45(2), 198 (2000).
65. Lévy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can. J. Clin. Pharmacol. 14(2), e234-e239 (2007).
66. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr. Res. 82(1), 115-117 (2006).
67. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin. Neuropharmacol. 28(4), 169-175 (2005).
68. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin. Neuropharmacol. 24(5), 290-294 (2001).
69. Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol. Res. 52(5), 392-394 (2005).
70. Millson RC, Owen JA, Lorberg GW, Tackaberry L. Topiramate for refractory schizophrenia. Am. J. Psychiatry 159(4), 675 (2002).
71. Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J. Clin. Psychiatry 64(10), 1267-1268 (2003).
72. Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? J. Clin. Psychiatry 65(8), 1145 (2004).
73. Tiihonen J, Halonen P, Wahlbeck K et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, doubleblind, placebo-controlled, crossover trial. J. Clin. Psychiatry 66(8), 1012-1015 (2005).
74. Afshar H, Roohafza H, Mousavi G et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J. Psychopharmacol. DOI: 10.1177/0269881108089816 (2008) (Epub ahead of print).
75. Arnone D. Review of the use of topiramate for treatment of psychiatric disorders. Ann. Gen. Psychiatry 4(1), 5 (2005).
76. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can. J. Psychiatry 43(3), 305 (1998).
77. Megna JL, Devitt PJ, Sauro MD, Dewan MJ. Gabapentin's effect on agitation in severely and persistently mentally ill patients. Ann. Pharmacother. 36(1), 12-16 (2002).
78. Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int. Clin. Psychopharmacol. 20(3), 179-181 (2005).
79. Hardoy MC, Carta MG, Carpiniello B et al. Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up. J. Affect. Disord. 75(2), 125-130 (2003).
80. Jablonowski K, Margolese HC, Chouinard G. Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Can. J. Psychiatry 47(10), 975-976 (2002).
81. Ketter TA, Wang PW, Nowakowska C, Marsh WK. New medication treatment options for bipolar disorders. Acta Psychiatr Scand. 422(Suppl.), 18-33 (2004).
82. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 68(11), 1691-1700 (2007).
83. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin. Exp. Res. 32(8), 1429-1438 (2008).
84. Semenchuk MR, Labiner DM. Gabapentin and lamotrigine: prescribing guidelines for psychiatry. J. Pract. Psychiatry Behav. Health 3, 334-342 (1997).
85. Popova E, Leighton C, Bernabarre A, Bernardo M, Vieta E. Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Rev. Neurother. 7(6), 617-626 (2007).
86. Centorrino F, Albert MJ, Berry JM et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord. 5(5), 370-374 (2003).
87. Leweke FM, Gerth CW, Koethe D et al. Oxcarbazepine as an adjunct for schizophrenia. Am. J. Psychiatry 161(6), 1130-1131 (2004).
88. Baird P. The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J. Clin. Psychopharmacol. 23(4), 419 (2003).
89. Pratoomsri W, Yatham LN, Bond DJ, Lam RW, Sohn CH. Oxcarbazepine in the treatment of bipolar disorder: a review. Can. J. Psychiatry 51(8), 540-545 (2006).
90. Gerlach J, Thorsen K, Munkvad I. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double blind cross-over trial. Pharmakopsychiatr. Neuropsychopharmakol. 8(2), 51-56 (1975).
91. Small JG, Kellams JJ, Milstein V, Moore J. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am. J. Psychiatry 132(12), 1315-1317 (1975).
92. Kellams J, Small J, Milstein V, Perex H. Lithium combined with neuroleptics in the treatment of chronic schizophrenia. Psychopharmacol. Bull. 12(2), 27-30 (1976).
93. Carman J, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J. Clin. Psychiatry 42(3), 124-128 (1981).
94. Wilson WH. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. Psychopharmacology 111(3), 359-366 (1993).
95. Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr. Scand. 84(4), 150-154 (1991).
96. Schulz SC, Thompson PA, Jacobs M et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J. Clin. Psychiatry 60(6), 366-372 (1999). • Well-designed study of the adjunctive use of lithium for the treatment of schizophrenia, and conducted relatively recently.
97. Johnstone EC, Crow TJ, Frith CD, Owens D. The Northwick Park "functional" psychosis study: diagnosis and treatment response. Lancet 2(8603), 119-125 (1988).
98. Johnstone EC, Crow TJ, Owens D, Frith C. The Northwick Park 'functional' psychosis study. Phase 2 - maintenance treatment. J. Psychopharmacol. 5(4), 388-395 (1991).
99. Terao T, Oga T, Nozaki S et al. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study. Acta Psychiatr. Scand. 92(3), 220-224 (1995).
100. Hogarty GE, McEvoy JP, Ulrich RF et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch. Gen. Psychiatry 52(1), 29-41 (1995).
101. Huang LG, Bowden CL. Platelet monoamine oxidase response to lithium treatment in psychiatric patients. J. Clin. Psychopharmacol. 4(6), 326-331 (1984).
102. Leucht S, KisslingW, McGrath J. Lithium for schizophrenia. Cochrane Database Syst. Rev. 3, CD003834 (2007). •• Comprehensive meta-analysis with many pertinent references.
103. Adityanjee. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am. J. Psychiatry 152(4), 648-649 (1995).
104. Silverstone PH. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J. Clin. Psychopharmacol. 18(1), 86-88 (1998).
105. Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int. Clin. Psychopharmacol. 13(3), 137-140 (1998).
106. Boshes RA, Manschreck TC, Desrosiers J, Candela S, Hanrahan-Boshes M. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann. Clin. Psychiatry 13(4), 233-237 (2001).
107. Kutscher EC, Robbins GP, Kennedy WK, Zebb K, Stanley M, Carnahan RM. Clozapine-induced leukopenia successfully treated with lithium. Am. J. Health Syst. Pharm. 64(19), 2027-2031 (2007).
108. Ghaznavi S, Nakic M, Rao P et al. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am. J. Psychiatry 165(7), 813-818 (2008).
109. Sporn A, Gogtay N, Ortiz-Aguayo R et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J. Child Adolesc. Psychopharmacol. 13(3), 401-404 (2003).
110. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J. Clin. Psychiatry 67(5), 756-760 (2006).
111. Ferrier IN, Ferrie LJ, Macritchie KA. Old drug, new data. Revisiting lithium therapy. Adv. Psychiatr. Treat. 12(4), 256-264 (2006).
112. Coffey CE, Ross DR. Treatment of lithium/neuroleptic neurotoxicity during lithium maintenance. Am. J. Psychiatry 137(6), 736-737 (1980).
113. Spring G, Frankel M. New data on lithium and haloperidol incompability. Am. J. Psychiatry 138(6), 818-821 (1981).
114. Miodownik C, Alkatnany A, Frolova K, Lerner V. Delirium associated with lithium-quetiapine combination. Clin. Neuropharmacol. 31(3), 176-179 (2008).
115. Goldney R, Spence N. Safety of the combination of lithium and neuroleptic drugs. Am. J. Psychiatry 143(7), 882-884 (1986).
116. Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr. Res. 35(Suppl.), S23-S33 (1999).
117. Citrome L. Schizophrenia and valproate. Psychopharmacol. Bull. 37(Suppl. 2), 74-88 (2003).
118. Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13(9), 1102-1107 (2007). •• Landmark clinical trial report of a new antipsychotic agent with a novel mechanism of action.
119. Josiassen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 162(1), 130-136 (2005).
120. Anil Yaǧcioǧlu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry 66(1), 63-72 (2005).
121. Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med. 354(5), 472-482 (2006).
122. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr. Res. 92(1-3), 90-94 (2007).
123. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(6), 1386-1392 (2008).
124. Chang JS, Ahn YM, Park HJ, Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 69(5), 720-731 (2008).
125. Buchanan RW, Javitt DC, Marder SR et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164(10), 1593-1602 (2007).
126. US FDA. Information for Healthcare Professionals, Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). FDA Alert 12 Dec 2007. www.fda.gov/Cder/dayrug/InfoSheets/HCP/carbamazepineHCP.htm (Accessed 22 July 2008)
127. Abbott Laboratories. ABT-711 M02-547 Clinical Study Report. Available at: www.clinicalstudyresults.org/dayocuments/company-study_782_0.pdf (Accessed 20 November 2006)